000			03068cam a2200409 a 4500
005			20250918162151.0
008			120523s2012 enk b 001 0 eng
020			_a9780521195768 (hardback) _cRM288.80
020			_a0521195764 (hardback)
039		9	_a201310231227 _badnan _c201310111224 _dmasrul _c201305311003 _dsa'diah _y05-23-2012 _zsa'diah
040			_aDLC _cDLC _dYDX _dBTCTA _dUKMGB _dNLE _dCDX _dEUW _dYDXCP _dBWX _dPIT _dE7B _dUPM _dOCLCQ _dDLC _dUKM
090			_aC73.7.D66F647 2
090			_aC73.7.D66 _bF647 2
100	1		_aFovargue, Sara, _d1971-
245	1	0	_aXenotransplantation and risk : _bregulating a developing biotechnology / _cSara Fovargue.
260			_aCambridge : _bCambridge University Press, _c2012.
300			_axiii, 291 p. ; _c24 cm.
490	1		_aCambridge law, medicine and ethics
504			_aIncludes bibliographical references and index.
505	0		_aIntroducing the issues -- Dealing with risk -- Regulating experimental procedures and medical research -- Regulatory responses to developing biotechnologies -- Challenges to legal and ethical norms : first party consent and third parties at risk -- Surveillance and monitoring : balancing public health and individual freedom -- Summary and concluding thoughts : looking to the future.
520			_a'Some developing biotechnologies challenge accepted legal and ethical norms because of the risks they pose. Xenotransplantation (cross-species transplantation) may prolong life but may also harm the xeno-recipient and the public due to its potential to transmit infectious diseases. These trans-boundary diseases emphasise the global nature of advances in health care and highlight the difficulties of identifying, monitoring and regulating such risks and thereby protecting individual and public health. Xenotransplantation raises questions about how uncertainty and risk are understood and accepted, and exposes tensions between private benefit and public health. Where public health is at risk, a precautionary approach informed by the harm principle supports prioritising the latter, but the issues raised by genetically engineered solid organ xenotransplants have not, as yet, been sufficiently discussed. This must occur prior to their clinical introduction because of the necessary changes to accepted norms which are needed to appropriately safeguard individual and public health'-- _cProvided by publisher.
650		0	_aXenografts.
650		0	_aTransplantation immunology.
650		0	_aXenografts _xMoral and ethical aspects.
650		0	_aTransplantation of organs, tissues, etc.
650		0	_aTransplantation, Heterologous.
650		0	_aTransplantation, Heterologous _xethics.
650		0	_aTransplantation, Heterologous _xlegislation & jurisprudence.
830		0	_aCambridge law, medicine, and ethics.
907			_a.b15377891 _b2019-11-12 _c2019-11-12
942			_c01 _n0 _kC73.7.D66F647 2
914			_avtls003502415
990			_amab
991			_aFakulti Undang-Undang
998			_au _b2012-10-05 _cm _da _feng _genk _y0 _z.b15377891
999			_c521392 _d521392